This is the first blog in a series covering the Fiscal Year 2025 National Defense Authorization Act (“FY 2025 NDAA”). This first blog will cover: (1) NDAA sections affecting acquisition policy and contract administration that may be of greatest interest to government contractors; (2) initiatives that underscore Congress’s commitment to strengthening cybersecurity, both domestically and
Latest from Covington & Burling LLP - Page 16
ICO Audit on AI Recruitment Tools
On November 6, 2024, the UK Information Commissioner’s Office (ICO) released its AI Tools in recruitment audit outcomes report (“Report”). This Report documents the ICO’s findings from a series of consensual audit engagements conducted with AI tool developers and providers. The goal of this process was to assess compliance with data protection law, identify any
Just Weeks After COP16: CBD Secretariat Launches Stakeholder Consultations for the Operationalization of the DSI Mechanism. How Should Companies Engage?
The Secretariat of the Convention on Biological Diversity (CBD) has opened four consultations inviting stakeholder input on the development of the new Multilateral Mechanism on Benefit-Sharing (MLM) for Digital Sequence Information (DSI), including the establishment of the global benefit-sharing fund known as “The Cali Fund.”
Companies are encouraged to actively participate in these consultations
FTC Settles Case Against Provider of AI-Enabled Security Systems
On Tuesday, November 26, the FTC released a proposed settlement order with Evolv Technologies, a provider of AI-enabled security screening systems. The FTC’s complaint in the matter alleged that Evolv violated Section 5 of the FTC Act by making “false or unsupported claims” about the capabilities of an AI-enabled screening system that it provides to
U.S. AI Policy Expectations in the Trump Administration, GOP Congress, and the States
The results of the 2024 U.S. election are expected to have significant implications for AI legislation and regulation at both the federal and state level.
Like the first Trump Administration, the second Trump Administration is likely to prioritize AI innovation, R&D, national security uses of AI, and U.S. private sector investment and leadership in AI.
“Security, Europe!” Priorities of the Polish Presidency of the EU Council
From January to June 2025, Poland will hold the Presidency of the Council of the European Union, presenting an ambitious agenda organized around the concept of security to tackle some of the EU’s most pressing challenges. This blog outlines the announced focus areas for technology, trade, defense, and ESG. Each of these topics is pivotal
November 2024 Developments Under President Biden’s AI Executive Order
In a new post on the Inside Government Contracts blog, our colleagues provide the November 2024 update to our ongoing series on the implementation of Executive Order No. 14110 on the “Safe, Secure, and Trustworthy Development and Use of Artificial Intelligence” (the “AI EO”), issued by President Biden on October 30, 2023. The blog
Health Privacy Developments to Watch in 2025
2024 was an incredibly busy year for health privacy. As the year draws to a close and we look ahead to 2025, we share several areas that we are watching in the coming year, which we expect to be similarly busy with federal- and state-level activity:
Policy Implications for Europe Under a Second Trump Administration
As the world anticipates the return of Donald Trump to the White House, the European Union (“EU”) braces for significant impacts in various sectors. The first Trump administration’s approach to transatlantic relations was characterized by unpredictability, tariffs on imported goods, a strained NATO relationship, and withdrawal from the Iran nuclear deal and the Paris climate
MHRA Consults on New UK Pre-Market Medical Device Measures
Last month we provided an update on the UK Government’s draft post-market surveillance statutory instrument (“PMS SI”) and the UK Medicines and Healthcare products Regulatory Agency’s (“MHRA’s”) intention to run a further public consultation on proposed changes to pre-market medical device regulation under an upcoming statutory instrument (“Pre-Market SI”).
On 14 November 2024, the MHRA